June 9, 2017 | In preparation for the Next Generation Dx Summit in Washington DC this August, Liz Worthey, Faculty Investigator and Director at HudsonAlpha Institute for Biotechnology, sat down to discuss her work in whole genome sequencing to diagnose and monitor rare diseases. She discusses her team’s work with standardizing NGS tests, utilizing sequencing as a diagnostic test, and challenges to making whole genome sequencing standard of care in clinical practice.
Next Generation Dx